Skip to main content
. Author manuscript; available in PMC: 2016 Jan 8.
Published in final edited form as: Drug Discov Today. 2014 Aug 27;19(12):1964–1970. doi: 10.1016/j.drudis.2014.08.011

Figure 2.

Figure 2

Structural comparison of an E2 segment spanning residues 412–423 in 4MWF and co-crystallized with neutralizing murine mAb AP33 (PDB ID: 4GAJ). (a) The 4MWF structure in cyan, solved portion of residues 412–423 in red. (b) A zoomed in representation of these residues in red, the remaining is transparent. (c) E2 residues 412–423 in 4GAJ structure.